The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | HCC clinical trial data from ESMO 2018
Robin Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her thoughts on exciting clinical trial data in hepatocellular carcinoma (HCC) being presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Kelley begins by discussing the benefits of ramucirumab in sub-groups of patients with high alpha-fetoprotein (AFP), from the REACH I (NCT01140347) and REACH II (NCT02435433) studies. These results differed from those seen in the CELESTIAL study (NCT01908426), in which cabozantinib resulted in an improvement on a larger range of AFP positive patients. At this ESMO meeting, the role of checkpoint inhibition in immunotherapy for HCC is also being considered, with data to be presented on SHR-1210 in patients who have previously received sorafenib.
